This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
H. Lundbeck A/S
Drug Names(s): Lu AA47070
Description: Lu AA47070 is an adenosine receptor antagonist.
Lundbeck has not disclosed what type of adenosine receptor the drug targets, but adenosine A2A receptors have been suggested to be a benefit in Parkinson Disease. Adenosine A2A receptors are almost exclusively found on dopamine D2 receptor–bearing striatopallidal neurons and secrete the neurotransmitter GABA, which has an inhibitory effect. It is thought that the reduction in dopamine seen in Parkinson's disease leads to overactivity in these neurons, and blockade of adenosine A2A receptors may enhance the effects of dopamine on these neurons, thereby suppressing their inhibitory output. Adenosine A2A blockade has also demonstrated neuroprotective effects in animal models.
Lu AA47070 News
Additional information available to subscribers only: